How to Personalize Your Risk Assessment for Patients With DCIS

One of the challenges with DCIS is that we don't know which person who has DCIS is necessarily going to progress to developing invasive cancer. Over the last several years, people have gotten a lot better at risk-stratifying DCIS. There are some newer tests that look at gene expression. And then there's also a test called decision RT, which looks at some protein expression by immunohistochemistry in combination with other clinical features so that patients can decide whether or not they want to add radiation. OK, great. When do we do Sentinel lymph node biopsies and patients with DCIS?